Abstract:B-Raf is a member of the RAF family of serine/threonine kinases: it mediates cell, division, differentiation, and apoptosis signals through the RAS-RAF-MAPK pathway. Thus B-Raf is of keen interest in cancer therapy, such as melanoma. In this study, we propose the first Combination approach to integrate the pharmacophore (PhModel), CoMFA, and CoMSIA models for B-Raf, and this approach could be used for screening and optimizing potential B-Raf inhibitors in silico. Ten PhModels were generated based on the HypoGen BEST algorithm with the flexible fit method and diverse inhibitor structures. Each PhModel was designated to the alignment rule and screening interface for CoMFA and CoMSIA models. Therefore, CoMFA and CoMSIA models could align and recognize diverse inhibitor structures. We used two quality validation methods to test the predication accuracy of these combination models In the previously proposed combination approaches, they have a common factor in that the number of training set inhibitors is greater than that of testing set inhibitors. In our study, the 189 known diverse series B-Raf inhibitors, which are 7-fold the number of training set inhibitors, were used as a testing set in the partial least-squares validation. The best validation results were made by the CoMFA09 and CoMSIA09 models based on the Hypo09 alignment model. The predictive r(pred)(2) values of 0.56 and 0.56 were derived from the CoMFA09 and CoMSIA09 models, respectively. The CoMFA09 and CoMSIA09 models also had a satisfied predication accuracy of 77.78% and 80%, and the goodness of hit test score of 0.675 and 0.699, respectively. These results indicate that our combination approach could effectively identify diverse B-Raf inhibitors and predict the activity.

Development of Novel 3D-QSAR Combination Approach for Screening and Optimizing B-Raf Inhibitors in silico.

A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors

Molecular Docking and 3D-Qsar Studies on A Series of Fused Heterocyclic Amides As B-Raf Inhibitors

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

In Silico Design of New B-Raf Kinase Type-II Inhibitors Through Combined Molecular Modeling Studies

Accurate Activity Predictions of B-Raf Type Ii Inhibitors Via Molecular Docking and Qsar Methods

3D-QSAR and docking studies on pyridopyrazinones as BRAF inhibitors

Virtual Screening of B-Raf Kinase Inhibitors: A Combination of Pharmacophore Modelling, Molecular Docking, 3D-QSAR Model and Binding Free Energy Calculation Studies

Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives As Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches.

Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization

Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold As Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies

Integrating docking scores and key interaction profiles to improve the accuracy of molecular docking: towards novel B-RafV600E inhibitors.

Design of potent B-Raf V600E inhibitors by multiple copy simulation search strategy.

Molecular Dynamics Simulation, Free Energy Calculation and Structure-Based 3D-QSAR Studies of B-RAF Kinase Inhibitors.

Identification of Novel B-RafV600E Inhibitors Employing FBDD Strategy

3D QSAR Studies on a Series of Potent and High Selective Inhibitors for Three Kinases of RTK Family

Design, Virtual Screening, Molecular Docking, ADME and Cytotoxicity Studies of 1,3,5-Triazine Containing Heterocyclic Scaffolds as Selective BRAF Monomeric, Homo and Heterodimeric Inhibitors

Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.

In silico high throughput screening and in vitro validation of a novel Raf/Mek dual inhibitor against colorectal carcinoma

Modification, Biological Evaluation and 3D QSAR Studies of Novel 2-(1,3-diaryl- 4,5-Dihydro-1h-pyrazol-5-yl)phenol Derivatives As Inhibitors of B-Raf Kinase.

QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors